Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bevan

Showing results (421-430 of 826) with videos related to

Pageof 83
Sort By:
JAMA Neurology|June 9, 2015
Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple SclerosisRegina Schlaeger, Nico Papinutto, Alyssa H Zhu, et al.
Journal of Medicinal Chemistry|March 26, 2009
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groupsPanayiotis A Procopiou, Victoria J Barrett, Nicola J Bevan, et al.
Journal of Medicinal Chemistry|May 14, 2010
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approachPanayiotis A Procopiou, Victoria J Barrett, Nicola J Bevan, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2008
Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2Osamu Irie, Takatoshi Kosaka, Masashi Kishida, et al.
Journal of Medicinal Chemistry|July 17, 2007
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetrationEdward K Dziadulewicz, Stuart J Bevan, Christopher T Brain, et al.
Annals of Neurology|September 30, 2014
Precision medicine in chronic disease management: The multiple sclerosis BioScreenPierre-Antoine Gourraud, Roland G Henry, Bruce A C Cree, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2008
Sulfonamido-aryl ethers as bradykinin B1 receptor antagonistsAndrew G Cole, Axel Metzger, Marc-Raleigh Brescia, et al.
Annals of Neurology|December 8, 2021
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple SclerosisAntje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Annals of Neurology|March 2, 2022
Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"Antje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Physical Review Letters|May 2, 2020
Measurements of the Absolute Branching Fractions of B^{±}→K^{±}X_{cc[over ¯]}J P Lees, V Poireau, V Tisserand, et al.
Pageof 83

Showing results (421-430 of 826) with videos related to

Sort By:
Pageof 83
JAMA Neurology|June 9, 2015
Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple SclerosisRegina Schlaeger, Nico Papinutto, Alyssa H Zhu, et al.
Journal of Medicinal Chemistry|March 26, 2009
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groupsPanayiotis A Procopiou, Victoria J Barrett, Nicola J Bevan, et al.
Journal of Medicinal Chemistry|May 14, 2010
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approachPanayiotis A Procopiou, Victoria J Barrett, Nicola J Bevan, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2008
Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2Osamu Irie, Takatoshi Kosaka, Masashi Kishida, et al.
Journal of Medicinal Chemistry|July 17, 2007
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetrationEdward K Dziadulewicz, Stuart J Bevan, Christopher T Brain, et al.
Annals of Neurology|September 30, 2014
Precision medicine in chronic disease management: The multiple sclerosis BioScreenPierre-Antoine Gourraud, Roland G Henry, Bruce A C Cree, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2008
Sulfonamido-aryl ethers as bradykinin B1 receptor antagonistsAndrew G Cole, Axel Metzger, Marc-Raleigh Brescia, et al.
Annals of Neurology|December 8, 2021
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple SclerosisAntje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Annals of Neurology|March 2, 2022
Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"Antje Bischof, Nico Papinutto, Anisha Keshavan, et al.
Physical Review Letters|May 2, 2020
Measurements of the Absolute Branching Fractions of B^{±}→K^{±}X_{cc[over ¯]}J P Lees, V Poireau, V Tisserand, et al.
Pageof 83